Publications by authors named "Milad Nasiri"
Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models.
Neurol Neuroimmunol Neuroinflamm
May 2022
Article Synopsis
- Siponimod is an oral medication approved for treating multiple sclerosis, showing promise in promoting remyelination and reducing inflammation in various mouse models of demyelination.
- In experiments, siponimod treatment led to improved remyelination in the cuprizone model and better visual function in the EAEON model, following a bell-shaped dose-response curve where moderate doses were more effective than high ones.
- The study highlights siponimod's immunomodulatory properties and its potential to shift microglial differentiation towards supporting myelin repair, suggesting that optimal dosing is crucial for maximizing its therapeutic effects.
While great advances have been made in the immunomodulatory treatment of multiple sclerosis (MS), there is still an unmet need for drugs with neuroprotective potential. Dimethyl fumarate (DMF) has been suggested to exert both immunomodulatory and neuroprotective effects in MS. To investigate if DMF has neuroprotective effects independent of immunomodulation we evaluated its effects in the non-inflammatory animal models of light-induced photoreceptor loss and optic nerve crush.
View Article and Find Full Text PDF